Provides ADC and other bioconjugate discovery, process development, and GMP manufacturing, including antibody intermediates and payload-linker capabilities.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public financial snapshot
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
Period
Currency / basis
Revenue
Net profit
Operating cash flow
Report
FY2025 2025-12-31
CNY IFRS / consolidated
5,944,245,000
1,480,496,000 Net income/(loss) attributable to owners of the parent
Consolidated group financials; not standalone CRO/CDMO segment revenue.
Source unit: CNY thousands; multiplied by 1000 to show absolute amounts.
Year-over-year changes were calculated from current/prior-period source amounts and rounded to two decimals. Conventional earnings growth is not shown for a negative prior-period base or a change from profit to loss.
Separately listed bioconjugate CRDMO controlled by WuXi Biologics; revenue overlaps with WuXi Biologics consolidated revenue.
H1 2026 includes part of the post-acquisition results of TOT BIOPHARM. Reported group revenue growth was 37.0%; the company separately presents figures excluding TOT BIOPHARM and constant-currency metrics. This record uses reported results at actual exchange rates.
2026H1 · Reporting notes
Consolidated group financials; not standalone CRO/CDMO segment revenue.
Source unit: CNY thousands; multiplied by 1000 to show absolute amounts.
Year-over-year changes were calculated from current/prior-period source amounts and rounded to two decimals. Conventional earnings growth is not shown for a negative prior-period base or a change from profit to loss.
Separately listed bioconjugate CRDMO controlled by WuXi Biologics; revenue overlaps with WuXi Biologics consolidated revenue.
H1 2026 includes part of the post-acquisition results of TOT BIOPHARM. Reported group revenue growth was 37.0%; the company separately presents figures excluding TOT BIOPHARM and constant-currency metrics. This record uses reported results at actual exchange rates.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Provides ADC and other bioconjugate discovery, process development, and GMP manufacturing, including antibody intermediates and payload-linker capabilities.
Listed as HKEX 02268; original 2025 annual and 2026H1 reports reviewed.
Program / service
Target / indication
Representative stage
Evidence & scope
Bioconjugate CRDMO
Not applicable (services/platform) · Drug research and manufacturing services for clients
Services / platform
Not applicable: service capabilities are not clinical drug candidates; E4 does not rate service quality.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Bio-S Pharmaceutical reported that its joint platform with XtalPi, Hangzhou Baijingyao Biotechnology, was unveiled in Shanghai on November 5. The partners described plans to combine AI-driven discovery with experimental validation, drug development, and clinical translation. The November 6 announcement presents an operating strategy and platform milestone, rather than a quantified licensing transaction or validated clinical outcome.
Fresenius signed an exclusive development agreement with WuXi Biologics providing access to up to 37 biosimilar candidates over the next decade. Initial work is expected to focus on polatuzumab vedotin and teprotumumab biosimilars. Fresenius retains selection flexibility and commercialization economics; the candidate count is an option-based opportunity, not 37 approved products.
Biocytogen reported consolidated revenue of RMB1.403 billion, up 49.09%, and attributable net income of RMB312.4 million for the nine months ended September 30, 2026. Attributable net income increased 173.77%. The group combines animal models, research services, and antibody licensing activities. The quarterly filing is unaudited and covers the year-to-date period.
Financials are consolidated figures for the listed group. Revenue by service line, available capacity, and project fit require further verification at the segment and operating-entity levels.
Consolidated figures overlap with those of the listed controlling parent. The entities may be compared independently but must not be added when estimating industry totals.
